Surfactant-based drug delivery systems for treating drug-resistant lung cancer

References

• Anand P, Sundaram C, Jhurani S, et al. (2008). Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 267:133–64
   PubMed Web of Science ®Google Scholar
• Bailey MM, Berkland CJ. (2009). Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29:196–212
   PubMed Web of Science ®Google Scholar
• Bansal T, Jaggi M, Khar R, Talegaonkar S. (2009). Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12:46–78
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Han H-Y, Alakhov VY, et al. (1998). Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm Res 15:850–5
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. (2008). Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Rel 130:98–106
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–10
   PubMed Web of Science ®Google Scholar
• Bonomi P, Kim K, Fairclough D, et al. (2000). Comparison of survival and quality of life in advanced non–small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–31
   PubMed Web of Science ®Google Scholar
• Brabender J, Danenberg KD, Metzger R, et al. (2001). Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850–5
   PubMed Web of Science ®Google Scholar
• Bunn P, Kelly, K. (1998). New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087–100
   PubMed Web of Science ®Google Scholar
• Chavanpatil MD, Patil Y, Panyam J. (2006). Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 320:150–6
   PubMed Web of Science ®Google Scholar
• Chen Y-T, Feng B, Chen L-B. (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev 13:3577–81
   PubMed Web of Science ®Google Scholar
• Chougule MB, Padhi BK, Misra, A. (2006). Nano-liposomal dry powder inhaler of amiloride hydrochloride. J Nanosci Nanotechnol 6:9–10
   Web of Science ®Google Scholar
• Collnot E-M, Baldes C, Wempe MF, et al. (2007). Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 4:465–74
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, et al. (2004). Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharma 278:119–31
   PubMed Web of Science ®Google Scholar
• Dabholkar RD, Sawant RM, Mongayt DA, et al. (2006). Polyethylene glycol–phosphatidylethanolamine conjugate (PEG–PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm 315:148–57
   PubMed Web of Science ®Google Scholar
• Davis W, Pfeiffer R, Quay J. (1970). Normal and promoted gastrointestinal absorption of water‐soluble substances I: induced rapidly reversible hyperabsorptive state in the canine fundic stomach pouch. J Pharm Sci 59:960–3
   PubMed Web of Science ®Google Scholar
• de Vore R, Johnson David, H. (2000). Chemotherapy for small cell lung cancer. lung cancer: principles and practice. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins
   Google Scholar
• Dickinson, E. (1992). Introduction to food colloids. Oxford, UK: Oxford University Press
   Google Scholar
• Du J, Lu W-L, Ying X, et al. (2009). Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood−brain barrier and survival of brain tumor-bearing animals. Mol Pharm 6:905–17
   PubMed Web of Science ®Google Scholar
• Eberhardt W, Korfee, S. (2003). New approaches for small-cell lung cancer: local treatments. Cancer Control 10:289–96
   PubMedGoogle Scholar
• Elkharraz K, Faisant N, Guse C, et al. (2006). Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharm 314:127–36
   PubMed Web of Science ®Google Scholar
• Emilienne Soma C, Dubernet C, Bentolila D, et al. (2000). Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21:1–7
   PubMed Web of Science ®Google Scholar
• Ettinger DS. (2002). Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer? Oncologist 7:226–33
   PubMed Web of Science ®Google Scholar
• Ferrara, N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 10:10–14
   Google Scholar
• Ferrara N, Gerber H-P, Lecouter, J. (2003). The biology of VEGF and its receptors. Nat Med 9:669–76
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber H-P, Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400
   PubMed Web of Science ®Google Scholar
• Föger F, Schmitz T, Bernkop-Schnürch, A. (2006). In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27:4250–5
   Google Scholar
• Folkman J, Merler E, Abernathy C, Williams, G. (1971). Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275–88
   PubMed Web of Science ®Google Scholar
• Fong KM, Sekido Y, Minna JD. (1999). Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 118:1136–52
   PubMed Web of Science ®Google Scholar
• Fossella FV, Devore R, Kerr RN, et al. (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354–62
   PubMed Web of Science ®Google Scholar
• Gagandeep G, Garg T, Malik B, et al. (2014). Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci 53:10–16
   PubMed Web of Science ®Google Scholar
• García Sar D, Aguado L, Montes Bayón M, et al. (2012). Relationships between cisplatin-induced adducts and DNA strand-breaks, mutation and recombination in vivo in somatic cells of Drosophila melanogaster, under different conditions of nucleotide excision repair. Mutat Res Genet Toxicol Environ Mutagen 741:81–8
   PubMed Web of Science ®Google Scholar
• Garg, T. (2014). Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol 20:1–8
   Google Scholar
• Garg T, Goyal AK. (2012). Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett 2:270–80
   Google Scholar
• Garg T, Goyal AK. (2014a). Biomaterial-based scaffolds – current status and future directions. Expert Opin Drug Deliv 11:767–89
   PubMed Web of Science ®Google Scholar
• Garg T, Goyal AK. (2014b). Liposomes: targeted and controlled delivery system. Drug Deliv Lett 4:62–71
   Google Scholar
• Garg T, Rath G, Goyal AK. (2014). Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. [Epub ahead of print]
   Google Scholar
• Garg T, Singh O, Arora S, Murthy, R. (2012). Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst 29:1–63
   PubMed Web of Science ®Google Scholar
• Garg T, Singh S, Goyal AK. (2013). Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst 30:369–409
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–44
   PubMed Web of Science ®Google Scholar
• Goyal AK, Rath G, Garg T. (2013a). Nanotechnological Approaches for Genetic Immunization. DNA RNA Nanobiotechnol Med Diagn Treat Dis 67–120
   Google Scholar
• Goyal G, Garg T, Malik B, et al. (2013b). Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv
   Google Scholar
• Greco FA, Gray JR, Thompson DS, et al. (2002). Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma. Cancer 95:1279–85
   PubMed Web of Science ®Google Scholar
• Griffin WC. (1955). Calculation of HLB values of non-ionic surfactants. Am Perfumer Essent Oil Rev 65:26–9
   Google Scholar
• Group, N-SCLCC. (1995). Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909
   PubMed Web of Science ®Google Scholar
• Guillemard V, Saragovi HU. (2004). Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23:3613–21
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Sosman JA, Spigel DR, et al. (2005). Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889–96
   PubMed Web of Science ®Google Scholar
• Hande, K. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514–21
   PubMed Web of Science ®Google Scholar
• Haura EB. (2001). Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8:326–36
   PubMedGoogle Scholar
• Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. (2006). Development of a respirable, sustained release microcarrier for 5‐fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 95:1114–26
   PubMed Web of Science ®Google Scholar
• Ho EA, Soo PL, Allen C, Piquette-Miller, M. (2007). Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Rel 117:20–7
   PubMed Web of Science ®Google Scholar
• Holmberg, K. (2003). Novel surfactants: preparation applications and biodegradability, revised and expanded. Florida, USA: CRC Press
   Google Scholar
• Hosomi Y, Shibuya M, Niho S, et al. (2011). Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Res 31:3449–56
   PubMed Web of Science ®Google Scholar
• Hunter TB, Manimala NJ, Luddy KA, et al. (2011). Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res 31:3193–204
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350:2335–42
   PubMed Web of Science ®Google Scholar
• Iffert T, Soldan M, Moeller A, Maser, E. (2000). Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro. Toxicology 144:189–95
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. Cancer J Clin 61:69–90
   PubMed Web of Science ®Google Scholar
• Kataria K, Sharma A, Garg T, et al. (2014). Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv Lett 4:79–86
   Google Scholar
• Kaur M, Garg T, Rath G, Goyal AK. (2014a). Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst 31:49–88
   PubMed Web of Science ®Google Scholar
• Kaur M, Malik B, Garg T, et al. (2014b). Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv
   Google Scholar
• Kaur R, Garg T, Malik B, et al. (2014c). Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv 1–6 . [Epub ahead of print]
   Web of Science ®Google Scholar
• Kelsey CR, Clough RW, Marks LB. (2006). Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J 12:283–8
   PubMed Web of Science ®Google Scholar
• Koziara JM, Whisman TR, Tseng MT, Mumper RJ. (2006). In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Rel 112:312–19
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Benoit J-P. (2006). Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Rel 112:208–13
   PubMed Web of Science ®Google Scholar
• Leighl, N. (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 19:S52-8
   Google Scholar
• Lin J-K. (2007). Molecular targets of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease. New York, USA: Springer
   Google Scholar
• Lo Y-L. (2003). Relationships between the hydrophilic–lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Rel 90:37–48
   PubMed Web of Science ®Google Scholar
• Massarelli E, Andre F, Liu D, et al. (2003). A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:55–61
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder, K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165–96
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. (2005). A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Research and Treatment. New York, NY: Springer 233 Spring Street, S6–6
   Google Scholar
• Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nat Rev Cancer 6:583–92
   PubMed Web of Science ®Google Scholar
• Novello S, Longo M, Levra MG. (2007). Toward therapies tailored to patient characteristics. J Thorac Oncol 2:S38–41
   PubMed Web of Science ®Google Scholar
• Nurwidya F, Takahashi F, Murakami A, Takahashi, K. (2012). Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 44:151–6
   PubMed Web of Science ®Google Scholar
• Ohe Y, Ohashi Y, Kubota K, et al. (2007). Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Annals Oncol 18:317–23
   PubMed Web of Science ®Google Scholar
• Parnami N, Garg T, Rath G, Goyal AK. (2013). Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol
   Google Scholar
• Patel NR, Rathi A, Mongayt D, Torchilin VP. (2011). Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 416:296–9
   PubMed Web of Science ®Google Scholar
• Patil Y, Sadhukha T, Ma L, Panyam, J. (2009). Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Rel 136:21–9
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67–74
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, et al. (2004). American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–53
   PubMed Web of Science ®Google Scholar
• Pore MM, Hiltermann TJN, Kruyt FA. (2013). Targeting apoptosis pathways in lung cancer. Cancer Lett 332:359–68
   PubMed Web of Science ®Google Scholar
• Rege BD, Kao JP, Polli JE. (2002). Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237–46
   PubMed Web of Science ®Google Scholar
• Riehm H, Biedler JL. (1972). Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res 32:1195–200
   PubMed Web of Science ®Google Scholar
• Roberti A, Sala DL, Cinti, C. (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug‐resistant tumors: current views and new therapeutic prospective. J Cell Physiol 207:571–81
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Lilenbaum RC. (2010). Small cell lung cancer: past, present, and future. Curr Oncol Rep 12:327–34
   PubMed Web of Science ®Google Scholar
• Rusch V, Klimstra D, Venkatraman E, et al. (1997). Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515–22
   PubMed Web of Science ®Google Scholar
• Saintigny P, Burger JA. (2012). Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13:287–97
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. (2006). Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 355:2542–50
   PubMed Web of Science ®Google Scholar
• Scagliotti G, de Marinis F, Rinaldi M, et al. (2002). Phase III randomized trial comparing three platinum-based doublets in advanced non–small-cell lung cancer. J Clin Oncol 20:4285–91
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. (2002). Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med 346:92–8
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Crowley J, van Houtte P, et al. (2007). The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2:1067–77
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–103
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal, A. (2012). Cancer statistics, 2012. Cancer J Clin 62:10–29
   PubMed Web of Science ®Google Scholar
• Singh H, Sharma R, Joshi M, et al. (2014a). Transmucosal delivery of docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol
   Google Scholar
• Singh O, Garg T, Rath G, Goyal AK. (2014b). Microbicides for the treatment of sexually transmitted hiv infections. J Pharm 1–18
   Google Scholar
• Smit E, Carney D, Harford P, et al. (1989). A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44:631–3
   PubMed Web of Science ®Google Scholar
• Smit EF, van Meerbeeck JP, Lianes P, et al. (2003). Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. J Clin Oncol 21:3909–17
   PubMed Web of Science ®Google Scholar
• Solans C, Kunieda, H. (1996). Industrial applications of microemulsions. New York, USA: Marcel Dekker
   Google Scholar
• Song XR, Cai Z, Zheng Y, et al. (2009). Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37:300–5
   PubMed Web of Science ®Google Scholar
• Št’astný M, Plocová D, Etrych T, et al. (2002). HPMA-hydrogels containing cytostatic drugs: kinetics of the drug release and in vivo efficacy. J Control Rel 81:101–11
   PubMed Web of Science ®Google Scholar
• Št’astný M, Strohalm J, Plocova D, et al. (1999). A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur J Cancer 35:459–66
   PubMed Web of Science ®Google Scholar
• Subramanian J, Waqar SN, Govindan, R. (2011). Targeted therapy in lung cancer: lessons learned from past experiences. J Thorac Oncol 6:S1786–8
   PubMed Web of Science ®Google Scholar
• Sung JC, Pulliam BL, Edwards DA. (2007). Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25:563–70
   PubMed Web of Science ®Google Scholar
• Suttipong M, Tummala NR, Kitiyanan B, Striolo, A. (2011). Role of surfactant molecular structure on self-assembly: aqueous SDBS on carbon nanotubes. J Phys Chem C 115:17286–96
   Web of Science ®Google Scholar
• Tummala NR, Striolo, A. (2009). SDS surfactants on carbon nanotubes: aggregate morphology. ACS Nano 3:595–602
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV. (2005). Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Rel 107:143–57
   PubMed Web of Science ®Google Scholar
• Vogelsang GB, Abeloff MD, Ettinger DS, Booker SV. (1985). Long-term survivors of small cell carcinoma of the lung. Am J Med 79:49–56
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Wu XY. (2006). Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Rel 116:275–84
   PubMed Web of Science ®Google Scholar
• Woodcock D, Linsenmeyer M, Chojnowski G, et al. (1992). Reversal of multidrug resistance by surfactants. Br J Cancer 66:62–8
   PubMed Web of Science ®Google Scholar
• Wozniak AJ, Crowley JJ, Balcerzak SP, et al. (1998). Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459–65
   PubMed Web of Science ®Google Scholar
• Wu J, Lu Y, Lee A, et al. (2007). Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10:350–7
   PubMed Web of Science ®Google Scholar
• Wu S-H, Hang L-W, Yang J-S, et al. (2010). Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade-and mitochondria-dependent pathways. Anticancer Res 30:2125–33
   PubMed Web of Science ®Google Scholar
• Xiao Yan L, McTan T, Lee H. (2005). In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 28:822–8
   PubMed Web of Science ®Google Scholar
• Yang S, Gursoy RN, Lambert G, Benita, S. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21:261–70
   PubMed Web of Science ®Google Scholar
• Yang W, Peters JI, Williams RO III. (2008). Inhaled nanoparticles – a current review. Int J Pharm 356:239–47
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng S-S. (2006a). The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly (lactide)–tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27:4025–33
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng S-S. (2006b). Self-assembled nanoparticles of poly (lactide)–vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 324:191–8
   PubMed Web of Science ®Google Scholar